Updates are available Correction dated 2020-11-26
Click to view Correction: https://doi.org/10.1038/s41467-020-20129-9
Updates are available Correction dated 2020-01-30
Click to view Correction: https://doi.org/10.1038/s41467-020-14427-5
-
Authors
Galstyan, Anna
Markman, Janet L. http://orcid.org/0000-0003-4691-2964
Shatalova, Ekaterina S.
Chiechi, Antonella
Korman, Alan J.
Patil, Rameshwar http://orcid.org/0000-0001-8820-8233
Klymyshyn, Dmytro
Tourtellotte, Warren G.
Israel, Liron L.
Braubach, Oliver http://orcid.org/0000-0003-2038-7954
Ljubimov, Vladimir A.
Mashouf, Leila A.
Ramesh, Arshia
Grodzinski, Zachary B.
Penichet, Manuel L.
Black, Keith L.
Holler, Eggehard http://orcid.org/0000-0001-8582-2190
Sun, Tao
Ding, Hui
Ljubimov, Alexander V.
Ljubimova, Julia Y.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA209921, EY13431)
- License Information
-
More Information
Article History
Received: 8 September 2018
Accepted: 1 August 2019
First Online: 28 August 2019
Change Date: 11 May 2023
Change Type: Clarification
Change Details: Editor’s Note: Readers are alerted that the reliability of the data reported in this article is currently in question. Appropriate editorial action will be taken once this matter is resolved.
Competing interests
: J.Y.L., E.H., A.V.L., and K.L.B. are officers and stockholders of Arrogene Nanotechnology, Inc., 8560 West Sunset Boulevard, Suite 424, Los Angeles, CA 90069, USA. R.P. and H.D. are stockholders of the same company. M.L.P. is a shareholder of Klyss Biotech, Inc. The Regents of the University of California are in discussions with Klyss to license M.L.P.’s technology to this firm; A.J.K. is an officer and stockholder of Bristol-Myers Squibb, 700 Bay Rd, Redwood City, CA 94063, USA. A.G., J.L.M., E.S.S., A.C., D.K., W.G.T., L.L.I., O.B., V.A.L., L.A.M., A.R., Z.B.G., and T.S. declare no competing interests.
